{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:14:47Z","timestamp":1789035287626,"version":"build-2803163510"},"reference-count":15,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Central nervous system (CNS) tumors represent the most common solid tumors of childhood and remain the leading cause of cancer-related mortality among pediatric patients [...]<\/jats:p>","DOI":"10.3390\/curroncol33090549","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:03Z","timestamp":1789031583000},"page":"549","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes and New Treatments in Pediatric Brain Tumors"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1394-7167","authenticated-orcid":false,"given":"Craig","family":"Erker","sequence":"first","affiliation":[{"name":"Division of iHOPE, Department of Pediatrics, University of Alberta, Edmonton, AB T6G 2R3, Canada"},{"name":"Stollery Children\u2019s Hospital, Edmonton, AB T6G 2B7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Perreault","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of Montreal, CHU Sainte-Justine, Montreal, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jnci\/djp148","article-title":"Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study","volume":"101","author":"Armstrong","year":"2009","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature22973","article-title":"The whole-genome landscape of medulloblastoma subtypes","volume":"547","author":"Northcott","year":"2017","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cam4.4553","article-title":"The comparison of acute toxicities associated with craniospinal irradiation between photon beam therapy and proton beam therapy in children with brain tumors","volume":"11","author":"Uemura","year":"2022","journal-title":"Cancer Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-021-03847-y","article-title":"Comparison of hypothyroidism, growth hormone deficiency, and adrenal insufficiency following proton and photon radiotherapy in children with medulloblastoma","volume":"155","author":"Aldrich","year":"2021","journal-title":"J. Neuro-Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00018-011-0898-9","article-title":"MAPK pathway activation in pilocytic astrocytoma","volume":"69","author":"Jones","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/neuonc\/noaf065","article-title":"A phase 2 PBTC study of selumetinib for recurrent\/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4","volume":"27","author":"Fangusaro","year":"2025","journal-title":"Neuro-Oncology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: The phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2023","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs. Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas","volume":"637","author":"Monje","year":"2024","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","article-title":"Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency","volume":"29","author":"Das","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41591-021-01581-6","article-title":"Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency","volume":"28","author":"Das","year":"2022","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kardani, K., Gil, J.S., and Rabkin, S.D. (2023). Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1206111"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1056\/NEJMoa1801109","article-title":"Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss","volume":"378","author":"Brock","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/549\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:57:50Z","timestamp":1789034270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090549"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090549","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}